期刊文献+

甲状腺乳头状癌与良性乳头状增生中p16、CD56蛋白表达特点及诊断价值 被引量:8

The expressional characteristics and diagnostic values of p16 and CD56 protein in the papillary thyroid carcinoma and benign papillary hyperplasia
下载PDF
导出
摘要 目的探讨p16与CD56标记在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)和良性乳头状增生(benign papillaryhyperplasia,BPH)中的表达特点与诊断价值。方法采用免疫组化EnVision两步法检测46例PTC及22例BPH中p16与CD56蛋白的表达。结果乳头状癌中p16阳性率以(+~)为主,分布呈癌巢中央区阳性率低、浸润性边缘阳性率高的特点,癌周组织(-)。CD56在80%的癌组织中表达缺失,其余病例呈(+~),癌周组织(+)。p16、CD56对PTC和BPH的诊断敏感度为98%、80%;特异度为82%、64%;准确度为93%、75%。两者平行联合检测,敏感度达100%,特异性降为55%,如串联联合,特异性升高为91%,敏感度率为78%。结论 p16蛋白是鉴别PTC与BPH的良好标记物,CD56对这两种病变的诊断价值有限,p16、CD56蛋白联合检测并不优越于p16单独标记。 Purpose To explore the expressional characteristics and differential utilities of p16 and CD56 protein in papillary thyroid carcinoma(PTC) and benign papillary hyperplasia(BPH).Methods p16 and CD56 expression were detected in 46 cases of PTC and 22 cases of BPH by immunohistochemistry method.Results p16 in PTC showed +~ positivity in most cases and displayed the features of dispersed distribution in central region and dense aggregation on the invasive margin,whereas was negative in the neighboring benign tissue.CD56 expression was lost in 80% of cases,while ﹢~ expression was observed in the rest cases.Positive staining of CD56 was present in the neighboring benign tissue.The sensitivity,specialty and accuracy of p16 and CD56 were 98%,82%,93% and 80%,64%,75% respectively.By combination of the two markers with parallel and serial patterns separately,the sensitivity and specialty were 100%,55% and 78%,91% in turn.Conclusions p16 could serve as an auxiliary marker in the differential diagnosis of PTC and BPH;However,CD56 may have a limited effect.The joint efficacy of the two markers seemingly is not more superior to that of p16 alone.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2011年第11期1214-1217,共4页 Chinese Journal of Clinical and Experimental Pathology
关键词 甲状腺肿瘤 乳头状癌 良性乳头状增生 免疫组化 P16 CD56 thyroid neopalsms papillany carcinoma benign papillary hyperplasia immunohistochemistry p16 CD56
  • 相关文献

参考文献16

  • 1Zidan J, Karen D, Stein M, et al. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival [ J ]. Cancer, 2003,97 (5) : 1181 - 5.
  • 2Christopher D M, Fletcher M D. Diagnostic histopathology of tumors [ M ].3rd ed. Toronto : Elsevier Press, 2007 : 1003 - 5.
  • 3柳剑英,廖松林,吴秉铨,张燕.免疫组化在甲状腺乳头状病变诊断中的意义探讨[J].中国肿瘤临床,2003,30(9):609-613. 被引量:5
  • 4nosisofthyroid cancer Gown A M, et al. Biomarker panel diaga critical review[ J]. Expert Rev Antican- cer Ther, 2008,8 (9) : 1399 - 413.
  • 5Wiseman S M, Melck A, Masoudi H, et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis [ J ]. Ann Surg Oncol, 2008,15 (10) :2811 - 26.
  • 6Barroeta J E, Baloch Z W, Lal P, et al. Diagnostic value of differ- ential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis [ J ]. Endocr Pathol, 2006,17 ( 3 ) :225 - 34.
  • 7李军,胡万宁.P16、P27蛋白在甲状腺肿瘤中的表达研究[J].现代肿瘤医学,2004,12(3):194-196. 被引量:4
  • 8Lam A K, Lo C Y, Leung P, et al. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma[J]. Ann Surg Oncol, 2007,14(5) :1772 -9.
  • 9Boltze C, Zack S, Quednow C,et al. Hypermethylation of the CD- KN2/pl6INK4A promotor in thyroid carcinogenesis [ J ]. Pathol Res Pract, 2003,199 (6) :399 - 404.
  • 10Dong Y, Walsh M D, McGuckin M A,et al. Increased expression of cyclin- dependent kinase inhibitor 2 (CDKN2A) gene product pl6INK4A in ovarian cancer is associated with progression and un- favorable prognosis[ J]. Int J Cancer, 1997,74( 1 ) :57 -63.

二级参考文献21

  • 1[1]LiVolsi VA. Surgical pathology of the thyroid [M]. W.B.Saunders company, 1990, 131
  • 2[2]Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours.2nd ed. WHO international histological classification of tumours [M]. Springer-Verlag, Berlin, 1988.11
  • 3[3]Fletcher CDM. Diagnostic histopathology of tumors[M]. 2ndd.Churchill Livingstone, 2000, 959
  • 4[4]Skov BG, Stahel RA, Hirsch F. ME1-antibody labelling of primary bronchogenic tumors and extrapulmonary malignancies [J]. Lung Cancer, 1994, 11(3~4): 221~227
  • 5[5]Miettinen M, Karkkainen P. Differential reactivity of HBME-1and CD15 antibodies in benign and malignant thyroid rumors.Preferential reactivity with malignant tumours [J]. Virchows Arch, 1996, 429(4~5): 213~219
  • 6[6]Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma[J]. Mod Pathol, 2001,14(4): 338~342
  • 7[7]Mai KT, Landry DC, Thomas J, et al. Follicular adenoma with papillary architecture; a lesion mimicking papillary thyroid carcinoma [J]. Histopathology, 2001, 39(1): 25~32
  • 8[8]From G, Mellemgaard A, Knudsen N, et al. Review of thyroid cancer cases among patients with previous benign thyroid disorders [J]. Thyroid, 2000, 10(8): 697~700
  • 9[9]Sugenoya A, Masuda H, Komatsu M, et al. Adenomatous goiter: therapeutic strategy, postoperative outcome, and study of epidermal growth factor receptor [J]. Br J Surg, 1992, 79(5):404~406
  • 10[10]Yamamoto Y, Maeda T, Izumi K, et al. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases [J].Cancer, 1990, 65(5): 1173~1179

共引文献7

同被引文献71

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部